VTGN Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit
VistaGen Therapeutics, Inc. (VTGN)
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vistagen.com
Company Research
Source: GlobeNewswire
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Vistagen Therapeutics, Inc. (VTGN) Misled Investors Regarding the Viability of its Trial Study of Fasedienol According to the complaint, defendants provided these overwhelmingly positive statements to investors while at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its Phase 3 PALISADE-3 trial study of
Show less
Read more
Impact Snapshot
Event Time:
VTGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTGN alerts
High impacting VistaGen Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VTGN
News
- ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGNGlobeNewswire
- VISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. and Encourages Investors to Contact the FirmGlobeNewswire
- VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Action Case with Johnson FistelGlobeNewswire
- Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmPR Newswire
- Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
VTGN
Earnings
- 11/13/25 - Miss
VTGN
Sec Filings
- 1/9/26 - Form 8-K
- 1/5/26 - Form 4
- 12/22/25 - Form 8-K
- VTGN's page on the SEC website